OBJECTIVES: Statins are the treatment of choice for lowering LDL-C levels and reducing cardiovascular events. Statins are given to people with at least 20%  risk of having a major vascular event within 10 years. They reduce risk of serious vascular events by 21 percent. Currently available statins in Slovakia are lovastatin, simvastatin, fluvastatin, atorvastatin, rosuvastatin METHODS: Data were abstracted from Slovak Institute for Drug Control. Key data for analysis including the number of medicine packages and financial expenditures are provided to SIDC  by wholesalers.  RESULTS: The highest consumption of statins within years 2008-2012 was observed in 2010 with total expenditures of 25.9 mil. € and with 3.5 prescribed packages. Financial expenditures rose gradually from 22.9 mil. € in 2008 to 25.9 mil. € in 2010  and subsequently declined to 25.3 mil. € in 2011. In first quartal of 2012 the downward trend continues with estimated annual decrease to 22.9 millions €.  Consumption expressed in number of packages flactuated from 2.8 mil. in 2008 to 3.3 in 2011, with expected downturn to 3.1 in 2012. Significant increase in number of issued packages was noted between 2008 and 2009, while financial expenditures exceeded their growth between 2009 and 2010. The most frequently used statin in Slovakia is atorvastatin (65% in 2011) followed by simvastatin (21% in 2011). The expenditures of rosuvastatin almost trippled in both financial and physical units within 2008-2011. The Lowest consumption showed lovastatin (0.9% in 2011).  CONCLUSIONS:  At present, there are 1469 medicines on the Slovak market including atorvastatin, while there are only 244 with simvastatin and 6 with lovastatin as active ingredient. The decrease in use of simavstatin might be also caused by appearance of its associated side-effects including myopathy. Rosuvastatin presents good alternative of treatment when the effectiveness of classic statins is not sufficient.